Astrazeneca Share Price (AZN)

MidBoy, we both cleaned up in RR !!!!! And continue too, I remember back in 20/21 hoovering those little nuggets up, proved a goldmine :-)

Long time to wait then. You snooze, you lose.

This will go back towards the £160 range once TRUMP/PUTIN stop pi55ing about with the world

Good news

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival

If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment

TOKYO--(BUSINESS WIRE)-- Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.

Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN).

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02 phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU.

In TROPION-Breast02, Datroway demonstrated a statistically significant and clinically meaningful 5.0-month improvement in median overall survival (OS) versus investigator’s choice of chemotherapy (hazard ratio [HR]=0.79; 95% confidence interval [CI]: 0.64-0.98; p=0.0291). Median OS was 23.7 months for patients treated with Datroway versus 18.7 months for those treated with chemotherapy. Datroway reduced the risk of disease progression or death by 43% compared to chemotherapy (HR=0.57; 95% CI: 0.47-0.69; p<0.0001) as assessed by blinded independent central review (BICR). Median progression-free survival (PFS) was 10.8 months for patients treated with Datroway versus 5.6 months for those treated with chemotherapy in patients with metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway was also associated with more robust treatment responses compared to chemotherapy, with an objective response rate (ORR) of 62.5% versus 29.3% for those treated with chemotherapy.

“Triple negative breast cancer remains one of the most aggressive types of breast cancer, with limited treatment options for patients with metastatic disease who are not candidates for immunotherapy and are currently treated with traditional chemotherapy,” said John Tsai, MD, Global Head, R&D, Daiichi Sankyo. “This positive recommendation by the CHMP underscores the potential for Datroway to replace traditional chemotherapy in this setting and we look forward to working closely with the EMA to bring this new indication to patients in the EU.”

AZN requires to close above 5/6/26 peak high, and similarly sector chart requires same. At present sp has rallied above the bearish daily outside price bar high of 13506, which could reverse the bearish view in the outside price bar. However the conservative view would require a close above 13878 high of 5/6/26 and at least a 2 day close either above the outside bar high of 13506, or a 2 day close below the outside bar low of 13116.

The sector at last looks, showed 8 risers to 10 falling equities. However sector chart rose today simply because the large capital equities are largely in the risers today.

I would suggest 3/6/26 open of 13082, as a support level, because the day was a Japanese hammer candlestick representing the lowest low in the bearish head & shoulder formation, with a confirmed 2 day close below that open of 13082, before assuming support has broken. There is also the market phenomenon of attachment to large numbers, so 13000 is likely to trading activity. DYOR.